HURST Corporate Finance advises Visible Analytics shareholders on sale to Newmarket Strategy

Visible Analytics, founded in 2018 and based in Oxford and Budapest, works with pharmaceutical and life sciences companies across a range of therapy areas, including oncology and rare disease.

Its team provides services including economic modelling, clinical trial analysis, data analytics, value communication, systematic reviews and evidence synthesis.

The HURST Corporate Finance team acting as lead advisers to Visible Analytics included Nigel Barratt, Matthew Taylor and Jack Deegan.

Newmarket Strategy is a specialist healthcare and life sciences consultancy based in London.

Founded in 2021, it has more than 40 staff working for clients across pharmaceuticals, medtech and healthcare services. The business is backed by US private equity firm Baird Capital, which took a minority stake in January 2025.

Matthew Taylor said: “Visible Analytics is an excellent example of the type of specialist, high-quality business that continues to attract strong strategic interest.

“The team has built a highly respected position in health economics and outcomes research, supported by technical depth, longstanding client relationships and a clear commitment to quality.

“We were pleased to support the shareholders through the transaction with Newmarket Strategy, and believe the combination provides a strong platform for the business’ next phase of development.”